The University of Oxford has held its position as the leading academic institution in the UK for generating spinout companies, according to a new report by data analyst firm Beauhurst.
Mental Health and Dementia are a global healthcare crisis, affecting over one billion people worldwide. Of those, over 400 million people are on the Alzheimer's disease continuum, with one person diagnosed every three seconds, and the figure expected to rise as the global population of those over 60 is set to double by 2050.
Nearly one billion people worldwide suffer from some form of mental disorder, according to UN data, but relatively few can access the treatment they need. Innovative AI based therapy, developed by researchers at Oxford, is now enabling a greater number of people to get help.
The University of Oxford has partnered with other institutions and investors to agree terms which will greatly increase the UK\u2019s capacity to turn world-leading research into spinouts that will generate economic growth and societal impact.
More spinout companies are created by the University of Oxford than any other UK University and an increasing number of their founders and senior leaders are women.
The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their \u201csmart\u201d bioelectronic implants.
Three University of Oxford spinouts have raised significant investment to scale their companies in vehicle automation, quantum computing and medical imaging respectively.
Last month the Oxford Innovation Society (OIS) hosted an event at Pembroke College which celebrated some of the pioneering translational research and innovation coming out of the University\u2019s Medical Sciences Division.
Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.
The University of Oxford has been awarded more than \u00a37 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation\u2019s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from UK research institutions.
The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation
The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.
Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.
Forget the TV clich\u00e9s about Oxford \u2013 all punting and pass the port. The 925-year-old university is full of the most amazing people who are helping and benefiting the world, well beyond the quads and spires, says Professor Chas Bountra, the university\u2019s Pro-Vice-Chancellor for Innovation.\r\n\r\nAfter the events of the last two years - and the COVID-19 vaccine [2.5 billion doses delivered and counting] - this most enthusiastic champion of Oxford maintains there can be no doubt, innovation is part and parcel of the historic university\u2019s future. Who knows what is coming next, he says, expectantly.
Exscientia and the University of Oxford's Target Discovery Institute (TDI) today announced the formation of Xcellomics \u2013 a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.
Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.
![\"Nanopore](\"https://www.medsci.ox.ac.uk/news/oxford-retains-top-spot-for-spinouts/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n